Search

Adaptive Phage Therapeutics just got FDA approval to test their expanding, polymicrobial phage library approach in the clinic. This is a big step, and shows that the FDA can be supportive of a personalized phage library approach to phage th

Kurt Selle (Locus Biosciences) and colleagues, in collaboration with NC State University, have published a new paper in mBio showing that phage-delivered programmable CRISPR therapeutics (recombinant phage expressing host genome-targeting C

Ella Balasa, who received phage therapy in 2019 (which she wrote about in Capsid & Tail earlier this year), has her own column in Cystic Fibrosis News Today called This Lung Life. Her newest article describes her participation in an FDA pan

Adaptive Phage Therapeutics just got FDA approval to test their expanding, polymicrobial phage library approach in the clinic. This is a big step, and shows that the FDA can be supportive of a personalized phage library approach to phage th

An early stage biotechnology company in Gaithersburg, MD is hiring an experienced microbiologist/phage biologist to join a team developing phage therapies.

Ella Balasa, who received phage therapy in 2019 (which she wrote about in Capsid & Tail earlier this year), has her own column in Cystic Fibrosis News Today called This Lung Life. Her newest article describes her participation in an FDA pan

An early stage biotechnology company in Gaithersburg, MD is hiring an experienced microbiologist/phage biologist to join a team developing phage therapies.

Kurt Selle (Locus Biosciences) and colleagues, in collaboration with NC State University, have published a new paper in mBio showing that phage-delivered programmable CRISPR therapeutics (recombinant phage expressing host genome-targeting C

Carmen Gu Liu (Baylor College of Medicine) and colleagues published a new preprint on phage-antibiotic synergy. They've created a comprehensive method for evaluating synergism, additivism, and antagonism for all antibiotic classes, (they're

STAT Madness has begun and there are 2 days left in round 1. Vote for the best biomedical innovations (in a "March Madness"-style format!). Phage therapy for alcoholic liver disease (UCSD) is in the running!

The Department of Medical Microbiology & Immunology at the University of Alberta invites applications for a Tier 2 Canada Research Chair tenure-track position at the assistant professor level. Seeking outstanding candidates with a strong re

Carmen Gu Liu (Baylor College of Medicine) and colleagues published a new preprint on phage-antibiotic synergy. They've created a comprehensive method for evaluating synergism, additivism, and antagonism for all antibiotic classes, (they're

STAT Madness has begun and there are 2 days left in round 1. Vote for the best biomedical innovations (in a "March Madness"-style format!). Phage therapy for alcoholic liver disease (UCSD) is in the running!

The Department of Medical Microbiology & Immunology at the University of Alberta invites applications for a Tier 2 Canada Research Chair tenure-track position at the assistant professor level. Seeking outstanding candidates with a strong re

Fernando Gordillo Altamirano (Monash University, Australia) and colleagues have published a new preprint on Acinetobacter baumannii phage resistance. They found that phage-resistant mutants were sensitive to complement, other phages, and an

Robert Schooley and Steffanie Strathdee wrote a commentary describing their take on the phage therapy case series published this month by the Iredell group, and on phage therapy as a field of growing importance. They consider this paper to

Luís Melo (University of Minho, Portugal) and colleagues have published a new review on the efficacy of preclinical phage therapy done in the last 10 years.

Fernando Gordillo Altamirano (Monash University, Australia) and colleagues have published a new preprint on Acinetobacter baumannii phage resistance. They found that phage-resistant mutants were sensitive to complement, other phages, and an

Robert Schooley and Steffanie Strathdee wrote a commentary describing their take on the phage therapy case series published this month by the Iredell group, and on phage therapy as a field of growing importance. They consider this paper to

The MDPI journal Antibiotics will publish a special issue on Phage Therapy: A biological Approach to Treatment of Bacterial Infections. The deadline for manuscript submissions is 31 March 2020. The journal Impact factor is 2.921. Please se